Persistent NKH with transient or absent symptoms and a homozygous GLDC mutation

Three of four nonketotic hyperglycinemia patients homozygous for a novel GLDC mutation (A802V) were treated by assisted respiration and/or sodium benzoate with or without ketamine and had transient neonatal or absent symptoms and normal developmental outcome, despite persisting biochemical evidence of nonketotic hyperglycinemia. This exceptional outcome may be related to the high residual activity of the mutant protein (32% of wild type) and therapeutic intervention during a critical period of heightened brain exposure and sensitivity to glycine. Ann Neurol 2004;56:139–143

[1]  R. Saul,et al.  POMGnT1 gene alterations in a family with neurological abnormalities , 2004, Annals of neurology.

[2]  A. Hamosh,et al.  Concerns regarding transience and heterozygosity in neonatal hyperglycenemia , 2003, Annals of neurology.

[3]  T. Coşkun,et al.  Transient nonketotic hyperglycinemia: two case reports and literature review. , 2003, Pediatric neurology.

[4]  T. Maeda,et al.  Heterozygous GLDC and GCSH gene mutations in transient neonatal hyperglycinemia , 2002, Annals of neurology.

[5]  S. Korman,et al.  Pitfalls in the diagnosis of glycine encephalopathy (non-ketotic hyperglycinemia). , 2002, Developmental medicine and child neurology.

[6]  C. Choi,et al.  Localized Proton MR Spectroscopic Detection of Nonketotic Hyperglycinemia in an Infant , 2001, Korean journal of radiology.

[7]  Y. Matsubara,et al.  Chromosomal localization, structure, single-nucleotide polymorphisms, and expression of the human H-protein gene of the glycine cleavage system (GCSH), a candidate gene for nonketotic hyperglycinemia , 2001, Journal of Human Genetics.

[8]  Wei Huang,et al.  In Vivo 1H Magnetic Resonance Spectroscopic Measurement of Brain Glycine Levels in Nonketotic Hyperglycinemia , 2001, Journal of neuroimaging : official journal of the American Society of Neuroimaging.

[9]  M. Coulter-Mackie,et al.  Biochemical and molecular investigations of patients with nonketotic hyperglycinemia. , 2000, Molecular genetics and metabolism.

[10]  A. Boneh,et al.  Prognostic clues and outcome of early treatment of nonketotic hyperglycinemia. , 1996, Pediatric neurology.

[11]  R. Schutgens.  The metabolic and molecular bases of inherited disease, seventh edition—3-volume set Edited by Charles R. Scriver, Arthur L. Beaudet, William S. Sly, and David Valle. New York, McGraw-Hill, 1995, $285.84 (xxxvi + 4605 pages and 93-page index), ISBN 0-07909-826-6 , 1995, Trends in Endocrinology & Metabolism.

[12]  P. Slater,et al.  Postnatal changes in N‐methyl‐D‐aspartate receptor binding and stimulation by glutamate and glycine of [3H]‐MK‐801 binding in human temporal cortex , 1993, British journal of pharmacology.

[13]  K. Narisawa,et al.  Identification of a common mutation in Finnish patients with nonketotic hyperglycinemia. , 1992, The Journal of clinical investigation.

[14]  K. Narisawa,et al.  Structural and expression analyses of normal and mutant mRNA encoding glycine decarboxylase: three-base deletion in mRNA causes nonketotic hyperglycinemia. , 1991, Biochemical and biophysical research communications.